Targeting Retinal Vascular Dysfunction for Blinding Eye Diseases

David A. Antonetti, PhD

Financial Disclosures: Consult with Novo Nordisk
Loss of Blood-Retinal Barrier in Blinding Eye Diseases

Diabetic Retinopathy
Uveitis
Vein Occlusion
CCL2

TNF

VEGF

aPKC
Inhibition of aPKC Prevents IR Induced Permeability

Small Molecule Inhibitor
Rat 1 Day IR

Tie2: dnPKCζ
Mouse 2 Day IR
Ischemia Causes Inflammatory Response
Inhibiting aPKC and Restoring Vascular Barrier Function
David Antonetti PhD

- dantonet@med.umich.edu
- Kellogg Eye Center U Michigan (Go Blue)
- Atypical protein kinase C (aPKC) inhibitor to control retinal vascular permeability and inflammation
- Retinal barrier restoration